LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

A first‐in‐human study of DS‐1040, an inhibitor of the activated form of thrombin‐activatable fibrinolysis inhibitor, in healthy subjects

Photo from wikipedia

Essentials DS‐1040 inhibits the activated form of thrombin‐activatable fibrinolysis inhibitor (TAFIa). Infusion of DS‐1040 was safe and well tolerated in healthy young and elderly subjects. DS‐1040 substantially decreased TAFIa activity… Click to show full abstract

Essentials DS‐1040 inhibits the activated form of thrombin‐activatable fibrinolysis inhibitor (TAFIa). Infusion of DS‐1040 was safe and well tolerated in healthy young and elderly subjects. DS‐1040 substantially decreased TAFIa activity but had no impact on bleeding time. DS‐1040 may provide an option of safer thrombolytic therapy.

Keywords: inhibitor; activated form; activatable fibrinolysis; fibrinolysis inhibitor; thrombin activatable; form thrombin

Journal Title: Journal of Thrombosis and Haemostasis
Year Published: 2017

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.